Dr. Van Meir and his colleagues have made many original contributions to cancer research. His team's research interest over the last 20 years has been in translational cancer research, with a major focus on neuro-oncology and more recently Ewing sarcoma and uveal melanoma.
Titles and Roles
- Professor, Departments of Neurosurgery and Hematology & Medical Oncology
- Emory University School of Medicine
- Leader, Cancer Cell Biology Research Program, and Director, Laboratory for Molecular Neuro-Oncology
- Winship Cancer Institute of Emory University
- Program Director, Emory Graduate Program in Cancer Biology
- Laney Graduate School, Emory University
- Research Program
- Cancer Cell Biology
Erwin Van Meir, PhD directs the Laboratory of Molecular Neuro-Oncology and participates in a multidisciplinary neuro-oncology team that designs new approaches for brain tumor therapy. He is the Founding Director of the Laney Graduate School's Cancer Biology Graduate Program and the Leader of the Cancer Cell Biology program at the Winship Cancer Institute. Dr. Van Meir has extensive experience in cancer research.
He was trained in molecular biology at the Universities of Fribourg and Lausanne, Switzerland where he obtained his PhD in 1989. Dr. Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego, and joined the Faculty of Emory University in 1998.
Dr. Van Meir and his colleagues have made many original contributions to cancer research. His team's research interest over the last 20 years has been in translational cancer research, with a major focus on neuro-oncology (gliomas and medulloblastomas) and more recently Ewing sarcoma and uveal melanoma. They strive to understand the molecular basis for human tumor development and how we can use this knowledge to devise new diagnostics and therapeutics that will improve patient survival.
They have further interest in identifying new biomarkers for neuro-oncology, using proteomic and metabolomic analyses of the cerebrospinal fluid. They aim to translate these novel biomarkers and therapeutic agents to testing in clinical trials with the hope to improve cancer patient treatment. The principal modeling systems they use are glioblastoma, medulloblastoma, and Ewing sarcoma, all highly malignant cancers, although the experimental therapeutics they develop are applicable to the cure of many solid malignancies.